Zhejiang Tianyu Pharmaceutical (300702) Fundamentals 2026 — P/E 77.1x, Revenue Analysis | SniperIQ
Zhejiang Tianyu Pharmaceutical (300702) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥7.2B, trading at ¥20.82 on the SHZ. This SniperIQ fundamentals page covers Zhejiang Tianyu Pharmaceutical's valuation (P/E 77.1x, P/B 2.0x), profitability (net margin 3.1%), revenue (¥3.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhejiang Tianyu Pharmaceutical's market cap?
Zhejiang Tianyu Pharmaceutical (300702) has a market capitalization of approximately ¥7.2B, trading at ¥20.82 on the SHZ. Market cap moves with the live share price.
What is Zhejiang Tianyu Pharmaceutical's P/E ratio?
Zhejiang Tianyu Pharmaceutical's trailing twelve-month P/E ratio is 77.1x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhejiang Tianyu Pharmaceutical?
Zhejiang Tianyu Pharmaceutical runs a net profit margin of 3.1%, a gross margin of 33.9%, and an operating margin of 4.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhejiang Tianyu Pharmaceutical generate?
Zhejiang Tianyu Pharmaceutical reported revenue of ¥3.1B for fiscal year 2025, with net income of ¥140M and earnings per share (EPS) of 0.41. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhejiang Tianyu Pharmaceutical pay a dividend?
Zhejiang Tianyu Pharmaceutical offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhejiang Tianyu Pharmaceutical financially healthy?
Zhejiang Tianyu Pharmaceutical carries a debt-to-equity ratio of 0.45x and a current ratio of 1.19x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhejiang Tianyu Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhejiang Tianyu Pharmaceutical (300702) the key facts are: market cap ¥7.2B, P/E 77.1x, revenue ¥3.1B, 52-week range 17.98-31.2. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhejiang Tianyu Pharmaceutical's full fundamentals live
Get Zhejiang Tianyu Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.